CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.20) by 50 percent. This is a 137.04 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $10.258 million which beat the analyst consensus estimate of $4.713 million by 117.68 percent. This is a 79.85 percent decrease over sales of $50.917 million the same period last year.